31 March 2020

The consensus statement "Joint RCOG, BSGE and BGCS guidance for the management of abnormal uterine bleeding in the evolving Coronavirus (COVID-19) pandemic" released on 30 March 2020 has received very positive feedback. However, in response to some comments received, the RCOG, BSGE and BGCS would like to make the following update:

In the section **Postmenopausal bleeding**

FROM (old version)

- A blind endometrial biopsy that produces an “insufficient sample” should be considered as normal provided the biopsy device was inserted more than 4 cm beyond the cervical canal, although this conclusion should be considered on a case by case basis (e.g. where the endometrium is markedly thickened, bleeding is heavy and / or there are increased risk factors for endometrial cancer).

TO (new version)

- A blind endometrial biopsy that produces an "insufficient sample" can be considered as normal provided the biopsy device was inserted more than 4 cm beyond the cervical canal (and ideally more than 6cm), although this conclusion should be considered on a case by case basis, taking into account individual patient risk factors and ultrasound findings. Women should be told to contact their GP if their bleeding symptoms recur so that further referral and investigation can be promptly arranged.

Reference 5 is now available: [https://www.preprints.org/manuscript/202003.0451/v1](https://www.preprints.org/manuscript/202003.0451/v1)